Regeneron and Sanofi have reached another milestone as they look to add to their megablockbuster immunology drug Dupixent a new U.S. indication for uncontrolled chronic obstructive pulmonary disease ...

The Food and Drug Administration (FDA) has accepted an application for Priority Review for dupilumab as an add-on therapy for adults with uncontrolled chronic obstructive pulmonary disease (COPD), ...

The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for mepolizumab as an add-on maintenance treatment for chronic obstructive pulmonary disease ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

This publication aims to improve treatment and care for adults with chronic obstructive pulmonary disease (COPD). It provides commissioners with strategies and recommendations for frontline care, ...

Study finds adults consuming more sugary drinks have higher odds of COPD, highlighting links between diet and lung health.

(RTTNews) - French drug major Sanofi (SNYNF, SNY) announced Friday that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application or sBLA ...

Findings from BOREAS and NOTUS showed dupilumab significantly reduced moderate to severe acute COPD exacerbations vs placebo. The Food and Drug Administration (FDA) has accepted for Priority Review ...

Meta-analysis finds AI performs well for Pulmonary Embolism detection on imaging, with lower accuracy in external validation.